Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach

Magnetic Resonance Imaging (MRI) has brought in several benefits to the study of Multiple Sclerosis (MS). It provides accurate measurement of disease activity, facilitates precise diagnosis, and aid in the assessment of newer therapies. The imaging guidelines for MS are broadly divided in to approaches for imaging patients with suspected MS or clinically isolated syndromes (CIS) or for monitoring patients with established MS. In this review, the technical aspects of MR imaging for MS are briefly discussed. The imaging process need to capture the twin aspects of acute MS viz. the autoimmune acute inflammatory process and the neurodegenerative process. Gadolinium enhanced MRI can identify acute inflammatory lesions precisely. The commonly applied MRI marker of disease progression is brain atrophy. Whole brain magnetization Transfer Ratio (MTR) and Magnetic Resonance Spectroscopy (MRS) are two other techniques use to monitor disease progression. A variety of imaging techniques such as Double Inversion Recovery (DIR), Spoiled Gradient Recalled (SPGR) acquisition, and Fluid Attenuated Inversion Recovery (FLAIR) have been utilized to study the cortical changes in MS. MRI is now extensively used in the Phase I, II and III clinical trials of new therapies. As the technical aspects of MRI advance rapidly, and higher field strengths become available, it is hoped that the impact of MRI on our understanding of MS will be even more profound in the next decade.

[1]  C. Guttmann,et al.  Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[2]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[3]  J L Ostuni,et al.  Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis , 2001, Multiple sclerosis.

[4]  R. Gold,et al.  Iron particle-enhanced visualization of inflammatory central nervous system lesions by high resolution: preliminary data in an animal model. , 2006, AJNR. American journal of neuroradiology.

[5]  Frederik Barkhof,et al.  Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.

[6]  David H. Miller,et al.  The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis , 2002, Journal of Neurology.

[7]  Frederik Barkhof,et al.  Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. , 2008, Brain : a journal of neurology.

[8]  J. Geurts Is progressive multiple sclerosis a gray matter disease? , 2008, Annals of neurology.

[9]  M. Rovaris,et al.  Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. , 2005, Archives of neurology.

[10]  Roland Martin,et al.  Therapeutic Potential of Phosphodiesterase-4 and -3 Inhibitors in Th1-Mediated Autoimmune Diseases , 2000, The Journal of Immunology.

[11]  Rohit Bakshi,et al.  Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. , 2004, Archives of neurology.

[12]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[13]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[14]  K. Selmaj,et al.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.

[15]  H. Waldmann,et al.  The window of therapeutic opportunity in multiple sclerosis , 2005, Journal of Neurology.

[16]  G. Comi,et al.  Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. , 1999, Magnetic resonance imaging.

[17]  G. Stoll,et al.  Gadofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. , 2008, Brain : a journal of neurology.

[18]  D. Knol,et al.  1 Persistent T 1 Hypointensity as an MRI Marker for Treatment Ef Þ cacy in Multiple Sclerosis , 2010 .

[19]  H. McFarland,et al.  Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.

[20]  David H. Miller,et al.  Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain , 2004, Annals of neurology.

[21]  N. Richert,et al.  Magnetization transfer imaging to monitor clinical trials in multiple sclerosis. , 1999, Neurology.

[22]  Kyle C. Kern,et al.  Regional hippocampal atrophy in multiple sclerosis. , 2008, Brain : a journal of neurology.

[23]  Frederik Barkhof,et al.  Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. , 2007, Archives of neurology.

[24]  F. Barkhof,et al.  A three-year, multi-parametric MRI study in patients at presentation with CIS , 2008, Journal of Neurology.

[25]  A. Thompson,et al.  Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis , 2009, Neurology.

[26]  T. Waldmann,et al.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. , 2009, Archives of neurology.

[27]  Ludwig Kappos,et al.  Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis , 1999, The Lancet.

[28]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[29]  Yunyun Duan,et al.  Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis. , 2008, European journal of radiology.

[30]  F. Barkhof,et al.  Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. , 1993, Brain : a journal of neurology.

[31]  P. Narayana,et al.  Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging , 2007, American Journal of Neuroradiology.

[32]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[33]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[34]  O. Kantarci,et al.  Gray Matter Atrophy Is Related to Long-Term Disability in Multiple Sclerosis , 2009 .

[35]  M Filippi,et al.  Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis , 1998, Annals of neurology.

[36]  A. Thompson,et al.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.

[37]  I. Allen,et al.  Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). , 1981, Acta neuropathologica. Supplementum.

[38]  N. Patronas,et al.  Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural history , 1991, Annals of neurology.

[39]  D. Miller,et al.  Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses , 2008, Multiple sclerosis.

[40]  R. Rudick,et al.  Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.

[41]  T. Waldmann,et al.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J A Frank,et al.  Time series for modelling counts from a relapsing-remitting disease: application to modelling disease activity in multiple sclerosis. , 1994, Statistics in medicine.

[43]  Anthony Traboulsee,et al.  Complementary information from multi-exponential T 2 relaxation and diffusion tensor imaging reveals differences between multiple sclerosis lesions , 2008, NeuroImage.

[44]  J. Frank,et al.  The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis , 1995, Annals of neurology.

[45]  J. Wolinsky,et al.  3D MPRAGE improves classification of cortical lesions in multiple sclerosis , 2008, Multiple sclerosis.

[46]  M W Weiner,et al.  A serial study of new MS lesions and the white matter from which they arise , 1998, Neurology.

[47]  M. Horsfield,et al.  A Magnetization Transfer MRI Study of Deep Gray Matter Involvement in Multiple Sclerosis , 2006, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[48]  James M Provenzale,et al.  Multiple sclerosis: diffusion tensor MR imaging for evaluation of normal-appearing white matter. , 2002, Radiology.

[49]  F. Barkhof,et al.  Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. , 1992, AJNR. American journal of neuroradiology.

[50]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[51]  À. Rovira,et al.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[52]  F Barkhof,et al.  The role of MRI as a surrogate outcome measure in multiple sclerosis , 2002, Multiple sclerosis.

[53]  A. Compston,et al.  Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench , 2004, Clinical Neurology and Neurosurgery.

[54]  C H Polman,et al.  MR spectroscopic evidence for glial increase but not for neuro‐axonal damage in MS normal‐appearing white matter , 2005, Magnetic resonance in medicine.

[55]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[56]  J. Duyn,et al.  Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. , 1998, AJNR. American journal of neuroradiology.

[57]  J A Frank,et al.  Serial contrast‐enhanced magnetic resonance imaging in patients with early relapsing–remitting multiple sclerosis: Implications for treatment trials , 1994, Annals of neurology.

[58]  Neal Jeffries,et al.  Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. , 2003, Brain : a journal of neurology.

[59]  H. Merkle,et al.  Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: Observations from a post-mortem 3 Tesla imaging study , 2009, Journal of the Neurological Sciences.

[60]  Frederik Barkhof,et al.  Regional DTI differences in multiple sclerosis patients , 2009, NeuroImage.

[61]  G. Barker,et al.  Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis , 1999, Neurology.

[62]  J. Duyn,et al.  Tissue-Specific Imaging Is a Robust Methodology to Differentiate In Vivo T1 Black Holes with Advanced Multiple Sclerosis–Induced Damage , 2009, American Journal of Neuroradiology.

[63]  Gareth J. Barker,et al.  Diffusion tensor imaging of post mortem multiple sclerosis brain , 2007, NeuroImage.

[64]  A. Thompson,et al.  The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results , 2001, Multiple sclerosis.

[65]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.